Evidence map›Paper›PMID 24455973›Full record

ArticleExpert review of anti-infective therapy2014

Tuberculosis screening and isoniazid preventive therapy implementation: a Brazilian experience.

Soumya Swaminathan, Padmapriyadarsini Chandrasekaran

Abstract readComment
PubMed Publisher
In one paragraph

Article in Expert review of anti-infective therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Soumya SwaminathanDepartment of Clinical Research, National Institute for Research in Tuberculosis, Chetput, Chennai 600 031, TN, India.
Padmapriyadarsini Chandrasekaran
National Institute of Research in Tuberculosis · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis Preventive therapy has been used since the 1960s for both mass treatment of populations and for targeted therapy to high-risk groups such as children. The World Health Organization (WHO) recommends the use of Isoniazid preventive therapy (IPT) as one of the strategies to reduce the TB burden among people living with HIV infection. However, its uptake in countries with high TB burden has been poor. One of the main barriers to its widespread implementation is concerns around the ruling out of active TB. WHO, in its revised guidelines on IPT, recommends the use of a symptom-based algorithm for TB screening. The randomized clinical trial evaluated here explores the effect of an intervention, in the form of training the clinic staff to screen for TB, use of tuberculin skin test and IPT to treat latent TB infection, and assess its effect on rates of TB and death in HIV infected.

Indexed as

Antitubercular AgentsFemaleHIV InfectionsHumansIsoniazidMaleTuberculosisAntitubercular AgentsIsoniazid

Identifiers

PMID24455973
OpenAlexW2016228441

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.